Zimmer Biomet Holdings (FRA:ZIM) Current Deferred Revenue: €0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:ZIM Zimmer Biomet Holdings Inc FRA:ZIM
82 GF Score
Price €83.82
GF Value €105.91
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Zimmer Biomet Holdings Current Deferred Revenue?

Zimmer Biomet Holdings FRA:ZIM +3.28% 82 Current Deferred Revenue is €0 Mil as of Jun. 2026. GuruFocus rates FRA:ZIM with a GF Score™ of 82/100 and a GF Value™ of €105.91 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Zimmer Biomet Holdings's current deferred revenue for the quarter that ended in Jun. 2026 was €0 Mil.

Zimmer Biomet Holdings Current Deferred Revenue Related Terms

Zimmer Biomet Holdings Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Zimmer Biomet Holdings's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zimmer Biomet Holdings Current Deferred Revenue Chart

Zimmer Biomet Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Zimmer Biomet Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:ZIM
82GF Score
Zimmer Biomet Holdings Inc FRA:ZIM
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of €0 Mil mean?
Zimmer Biomet Holdings (FRA:ZIM) has a Current Deferred Revenue of €0 Mil as of Jun. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Zimmer Biomet Holdings and its competitors.
Is Zimmer Biomet Holdings' Current Deferred Revenue too high?
Zimmer Biomet Holdings' current Current Deferred Revenue is €0 Mil. Overall, Zimmer Biomet Holdings has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zimmer Biomet Holdings' Current Deferred Revenue compare to STE and PEN?
Zimmer Biomet Holdings' Current Deferred Revenue of €0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Medical Devices & Instruments company?
A good Current Deferred Revenue depends on the Medical Devices & Instruments industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Zimmer Biomet Holdings and its competitors. Zimmer Biomet Holdings's current Current Deferred Revenue is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zimmer Biomet Holdings stock overvalued right now?
Based on GuruFocus' analysis, Zimmer Biomet Holdings (FRA:ZIM) is currently considered Modestly Undervalued. The stock's GF Value™ is €105.91, compared to a current price of €83.82 — trading 20.9% below its estimated fair value. The current Current Deferred Revenue is €0 Mil. Zimmer Biomet Holdings' overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Zimmer Biomet Holdings (FRA:ZIM), the current Current Deferred Revenue is €0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zimmer Biomet Holdings (FRA:ZIM) Overvalued in 2026?

Based on GuruFocus' analysis, Zimmer Biomet Holdings stock appears to be undervalued. The current stock price of €83.82 is trading 20.9% below its estimated GF Value™ of €105.91. GuruFocus considers Zimmer Biomet Holdings to be Modestly Undervalued.

Key valuation signals for FRA:ZIM:

  • Current Deferred Revenue: €0 Mil
  • GF Value™: €105.91 vs. price of €83.82 (20.9% below fair value)
  • GF Score™: 82/100 with 5 warning signs

No single metric tells the full story. See the FRA:ZIM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zimmer Biomet Holdings Business Description

Address 345 East Main Street, Warsaw, IN, USA, 46580
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
82GF Score

Get the complete analysis for FRA:ZIM

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€83.82
Price
€105.91
GF Value